Antimicrobial Properties of 8-Hydroxyserrulat-14-en-19-oic Acid for Treatment of Implant-Associated Infections

ABSTRACT Treatment options are limited for implant-associated infections (IAI) that are mainly caused by biofilm-forming staphylococci. We report here on the activity of the serrulatane compound 8-hydroxyserrulat-14-en-19-oic acid (EN4), a diterpene isolated from the Australian plant Eremophila neglecta. EN4 elicited antimicrobial activity toward various Gram-positive bacteria but not to Gram-negative bacteria. It showed a similar bactericidal effect against logarithmic-phase, stationary-phase, and adherent Staphylococcus epidermidis, as well as against methicillin-susceptible and methicillin-resistant S. aureus with MICs of 25 to 50 μg/ml and MBCs of 50 to 100 μg/ml. The bactericidal activity of EN4 was similar against S. epidermidis and its Δica mutant, which is unable to produce polysaccharide intercellular adhesin-mediated biofilm. In time-kill studies, EN4 exhibited a rapid and concentration-dependent killing of staphylococci, reducing bacterial counts by >3 log10 CFU/ml within 5 min at concentrations of >50 μg/ml. Investigation of the mode of action of EN4 revealed membranolytic properties and a general inhibition of macromolecular biosynthesis, suggesting a multitarget activity. In vitro-tested cytotoxicity on eukaryotic cells was time and concentration dependent in the range of the MBCs. EN4 was then tested in a mouse tissue cage model, where it showed neither bactericidal nor cytotoxic effects, indicating an inhibition of its activity. Inhibition assays revealed that this was caused by interactions with albumin. Overall, these findings suggest that, upon structural changes, EN4 might be a promising pharmacophore for the development of new antimicrobials to treat IAI.

[1]  U. Pennsylvania,et al.  Clinical and Laboratory Standards Institute , 2019, Springer Reference Medizin.

[2]  W. Zimmerli,et al.  Antimicrobial Agents in Orthopaedic Surgery , 2012, Drugs.

[3]  M. Otto.  Molecular basis of Staphylococcus epidermidis infections , 2012, Seminars in Immunopathology.

[4]  R. Landmann,et al.  Reversible Daptomycin Tolerance of Adherent Staphylococci in an Implant Infection Model , 2011, Antimicrobial Agents and Chemotherapy.

[5]  O. Cars,et al.  Protein Binding: Do We Ever Learn? , 2011, Antimicrobial Agents and Chemotherapy.

[6]  Yanmin Hu,et al.  A New Approach for the Discovery of Antibiotics by Targeting Non-Multiplying Bacteria: A Novel Topical Antibiotic for Staphylococcal Infections , 2010, PloS one.

[7]  P. Fey,et al.  Current concepts in biofilm formation of Staphylococcus epidermidis. , 2010, Future microbiology.

[8]  M. Hecker,et al.  Repair of Global Regulators in Staphylococcus aureus 8325 and Comparative Analysis with Other Clinical Isolates , 2010, Infection and Immunity.

[9]  I. Chopra,et al.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections , 2010, Nature Reviews Microbiology.

[10]  H. Rohde,et al.  Structure, function and contribution of polysaccharide intercellular adhesin (PIA) to Staphylococcus epidermidis biofilm formation and pathogenesis of biomaterial-associated infections. , 2010, European journal of cell biology.

[11]  Y. Dufrêne,et al.  Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. , 2009, Biochimica et biophysica acta.

[12]  M. Textor,et al.  Furanone at Subinhibitory Concentrations Enhances Staphylococcal Biofilm Formation by luxS Repression , 2009, Antimicrobial Agents and Chemotherapy.

[13]  P. Stewart,et al.  Daptomycin Rapidly Penetrates a Staphylococcus epidermidis Biofilm , 2009, Antimicrobial Agents and Chemotherapy.

[14]  K. Rentsch,et al.  Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant Staphylococcus aureus: Importance of Combination with Rifampin , 2009, Antimicrobial Agents and Chemotherapy.

[15]  Eve Neesham-Grenon,et al.  Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[16]  H. Nelis,et al.  Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. , 2008, Journal of microbiological methods.

[17]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[18]  H. Griesser,et al.  Antimicrobial compounds from the Australian desert plant Eremophila neglecta. , 2007, Journal of natural products.

[19]  Floyd E Romesberg,et al.  Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation , 2007, Nature Chemical Biology.

[20]  Chi P. Ndi,et al.  Antimicrobial activity of some Australian plant species from the genus Eremophila , 2007, Journal of basic microbiology.

[21]  K. Lewis.  Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.

[22]  Clinical,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard , 2006 .

[23]  E. Palombo,et al.  Characterisation of antibacterial Australian medicinal plant extracts by investigation of the mechanism of action and the effect of interfering substances , 2005, Journal of basic microbiology.

[24]  R. Finch,et al.  Telavancin: in vitro activity against staphylococci in a biofilm model. , 2005, The Journal of antimicrobial chemotherapy.

[25]  L. Mortin,et al.  Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. , 2005, The Journal of infectious diseases.

[26]  Deborah L. Higgins,et al.  Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[27]  S. Gibbons.  Anti-staphylococcal plant natural products. , 2004, Natural product reports.

[28]  Michael Otto,et al.  Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system , 2004, Cellular microbiology.

[29]  B. Timmermann,et al.  Antibacterial diterpenes from Calceolaria pinifolia. , 2003, Journal of natural products.

[30]  S. Semple,et al.  Antibacterial activity of Australian plant extracts against methicillin‐resistant Staphylococcus aureus (MRSA) and vancomycin‐resistant enterococci (VRE) , 2002, Journal of basic microbiology.

[31]  G. Cook,et al.  Phenotypic and molecular characterization of community occurring, Western Samoan phage pattern methicillin-resistant Staphylococcus aureus. , 2002, The Journal of antimicrobial chemotherapy.

[32]  T. Mattila-Sandholm,et al.  Fluorometric assessment of Gram‐negative bacterial permeabilization , 2000, Journal of applied microbiology.

[33]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[34]  A. D. Russell,et al.  Antiseptics and Disinfectants: Activity, Action, and Resistance , 1999, Clinical Microbiology Reviews.

[35]  P E Ochsner,et al.  Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. , 1998, JAMA.

[36]  Robert H. Gilman,et al.  Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay , 1998, Journal of Clinical Microbiology.

[37]  O. Kohashi,et al.  Morphology of defensin-treated Staphylococcus aureus , 1995, Infection and immunity.

[38]  I. Morrissey,et al.  Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition , 1994, Antimicrobial Agents and Chemotherapy.

[39]  A. Widmer,et al.  Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. , 1994, The Journal of antimicrobial chemotherapy.

[40]  A. D. Russell,et al.  Antibacterial activity of chlorhexidine. , 1993, The Journal of hospital infection.

[41]  J. Delves-Broughton.  The use of EDTA to enhance the efficacy of nisin towards Gram-negative bacteria , 1993 .

[42]  M. Vaara,et al.  Agents that increase the permeability of the outer membrane. , 1992, Microbiological reviews.

[43]  P. R. Jefferies,et al.  Diterpenes from Eremophila species , 1990 .

[44]  H. Neu,et al.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria , 1984, Antimicrobial Agents and Chemotherapy.

[45]  W. Zimmerli,et al.  Pathogenesis of foreign body infection: description and characteristics of an animal model. , 1982, The Journal of infectious diseases.

[46]  A. Cribb,et al.  Wild Medicine in Australia , 1981 .

[47]  W. Owens,et al.  Hemolytic mutants of group A Streptococcus pyogenes , 1978, Journal of clinical microbiology.

[48]  G. Kubica,et al.  Designation of Strain H37Rv as the Neotype of Mycobacterium tuberculosis , 1972 .

[49]  W. Hugo,et al.  The effect of chlorhexidine on the electrophoretic mobility, cytoplasmic constituents, dehydrogenase activity and cell walls of Escherichia coli and Staphylococcus aureus , 1966, The Journal of pharmacy and pharmacology.